A phase I clinical trial of [225Ac]Ac-labelled J591 reduces xerostomia and nephrotoxicity in metastatic castration-resistant PC (mCRPC) patients associated with radiolabelled PSMA-617 (138). Here, FOLH1 is linked to xerostomia.